JAK2 and cholangiocarcinoma: To explore how ruxolitinib, a JAK2 inhibitor, reduces ALDH1A3 expression in cholangiocarcinoma cells, we used a microarray to investigate the transcription factors that fluctuate the most when applying different ruxolitinib concentrations to a cholangiocarcinoma cell line.